Lupin Limited (BOM:500257)
India · Delayed Price · Currency is INR 2,413.95
-5.15 (-0.21%)
At close: Jul 31, 2026
Lupin Revenue
In the fiscal year ending March 31, 2026, Lupin had annual revenue of 279.58B INR with 23.12% growth. Lupin had revenue of 74.75B in the quarter ending March 31, 2026, with 31.89% growth.
Revenue
279.58B
Revenue Growth
+23.12%
P/S Ratio
3.95
Revenue / Employee
10.74M
Employees
26,021
Market Cap
1.10T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 279.58B | 52.50B | 23.12% |
| Mar 31, 2025 | 227.08B | 26.97B | 13.48% |
| Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
| Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
| Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Dr. Reddy's Laboratories | 331.19B |
| Torrent Pharmaceuticals | 157.23B |
| Jubilant Pharmova | 82.80B |
| Abbott India | 69.29B |
| Granules India | 56.32B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| GlaxoSmithKline Pharmaceuticals | 38.22B |
| AstraZeneca Pharma India | 22.76B |
Lupin News
- 12 days ago - Lupin Transfers Two Oncology Assets To Kaveri Therapeutics - Nasdaq
- 4 weeks ago - Lupin receives EIR from U.S. FDA for Somerset facility with VAI classification - Business Upturn
- 4 weeks ago - Lupin receives EMA approval for NaMuscla expansion for paediatric use - Business Upturn
- 5 weeks ago - Lupin Gets Tentative FDA Nod For Enzalutamide Tablets - Nasdaq
- 5 weeks ago - Lupin Wins FDA's Tentative Approval For Enzalutamide Tablets Across Multiple Strengths - Nasdaq
- 5 weeks ago - Lupin receives tentative approval from U.S. FDA for Enzalutamide tablets - Business Upturn
- 6 weeks ago - Lupin launches Azilsartan Medoxomil Tablets in the United States - Business Upturn
- 7 weeks ago - Lupin collaboraters with Spain’s ERN to launch Luforbec for Asthma and COPD treatment - Business Upturn